BRPI0819571A2 - "método para contracepção de emergência, pacote farmacêutico para contracepção de emergência e composição farmacêutica" - Google Patents

"método para contracepção de emergência, pacote farmacêutico para contracepção de emergência e composição farmacêutica"

Info

Publication number
BRPI0819571A2
BRPI0819571A2 BRPI0819571A BRPI0819571A BRPI0819571A2 BR PI0819571 A2 BRPI0819571 A2 BR PI0819571A2 BR PI0819571 A BRPI0819571 A BR PI0819571A BR PI0819571 A BRPI0819571 A BR PI0819571A BR PI0819571 A2 BRPI0819571 A2 BR PI0819571A2
Authority
BR
Brazil
Prior art keywords
emergency contraception
pharmaceutical
pharmaceutical composition
package
contraception
Prior art date
Application number
BRPI0819571A
Other languages
English (en)
Portuguese (pt)
Inventor
E Diliberti Charles
Original Assignee
Teva Womenss Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Womenss Health Inc filed Critical Teva Womenss Health Inc
Publication of BRPI0819571A2 publication Critical patent/BRPI0819571A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0819571A 2007-12-20 2008-12-19 "método para contracepção de emergência, pacote farmacêutico para contracepção de emergência e composição farmacêutica" BRPI0819571A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US828707P 2007-12-20 2007-12-20
PCT/US2008/013933 WO2009082478A1 (en) 2007-12-20 2008-12-19 Dosage regimens and pharmaceutical compositions and packages for emergency contraception

Publications (1)

Publication Number Publication Date
BRPI0819571A2 true BRPI0819571A2 (pt) 2019-09-24

Family

ID=40799234

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819571A BRPI0819571A2 (pt) 2007-12-20 2008-12-19 "método para contracepção de emergência, pacote farmacêutico para contracepção de emergência e composição farmacêutica"

Country Status (9)

Country Link
US (1) US20090170823A1 (enExample)
EP (1) EP2234491A4 (enExample)
JP (2) JP2011507853A (enExample)
AU (1) AU2008341138A1 (enExample)
BR (1) BRPI0819571A2 (enExample)
CA (1) CA2710293A1 (enExample)
EA (1) EA201070715A1 (enExample)
IL (1) IL206465A0 (enExample)
WO (1) WO2009082478A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007338843B2 (en) * 2006-12-20 2013-05-09 Teva Women's Health, Inc. Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof
FR2937862B1 (fr) * 2008-11-03 2010-11-19 Mohammed Ridha Chakroun Kit contraceptif
EP2381947A4 (en) 2008-12-23 2012-08-22 Quest Diagnostics Invest Inc MASS SPECTROMETRY ASSAY FOR STROGENIC COMPOUNDS
NZ595790A (en) * 2009-04-14 2013-11-29 Hra Pharma Lab Method for on-demand contraception
EP2999474A4 (en) 2013-05-21 2016-12-28 Predictive Therapeutics Llc THERAPEUTIC AND METHOD FOR USE

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684534A (en) 1985-02-19 1987-08-04 Dynagram Corporation Of America Quick-liquifying, chewable tablet
IE61236B1 (en) 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women
WO1994001412A1 (en) * 1992-07-01 1994-01-20 Ortho Pharmaceutical Corporation 1-arylsulphonyl, arylcarbonyl and 1-arylphosphonyl-3-phenyl-1,4,5,6-tetrahydropyridazines
DE4344463A1 (de) * 1993-12-22 1995-06-29 Schering Ag Kombinationsprodukt zur Kontrazeption
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
HU226566B1 (en) * 1994-10-24 2009-04-28 Schering Ag Use of competitive progesterone antagonists for producing pharmaceutical compositions for regulating female fertility as required
ZA9510926B (en) * 1994-12-23 1996-07-03 Schering Ag Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
AU2558297A (en) * 1996-05-16 1997-12-05 Gynetics Inc. Emergency contraceptive kit
FR2772617B1 (fr) * 1997-12-19 2001-03-09 Besins Iscovesco Lab Comprime de progesterone et son procede de preparation
US6368625B1 (en) 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
US6060078A (en) * 1998-09-28 2000-05-09 Sae Han Pharm Co., Ltd. Chewable tablet and process for preparation thereof
US6667050B1 (en) * 1999-04-06 2003-12-23 Galen (Chemicals) Limited Chewable oral contraceptive
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6399593B1 (en) * 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6660726B2 (en) 2000-03-10 2003-12-09 Endeavor Pharmaceuticals Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
HU227198B1 (en) * 2001-11-27 2010-10-28 Richter Gedeon Nyrt Pharmaceutical composition for emergency contraception containing levonorgestrel
US20030158432A1 (en) 2002-01-08 2003-08-21 Leonard Thomas W. Synthesis of a mixture of sulfated estrogens using a sulfur trioxide complex
HRP20040923A2 (en) * 2002-03-11 2004-12-31 Schering Ag 5-{2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino}-phtalide and related compounds with progesterone receptor modulating activity for use in fertility control and hormone replacement therapy
JP2005535624A (ja) 2002-06-25 2005-11-24 ワイス ホルモン関連症状の治療におけるシクロチオカルバメート誘導体の使用
EP1531806A4 (en) * 2002-06-25 2005-09-21 Wyeth Corp USE OF THIO-OXINDOLE DERIVATIVES IN THE TREATMENT OF HORMONE-RELATED DISEASES
EP1531824A4 (en) * 2002-06-25 2005-09-21 Wyeth Corp CYCLOTHIOCARBAMATIVE DERIVATIVES AS PR MODULATORS AND THEIR USE IN TREATING SKIN DISORDERS
EP1558618A1 (en) * 2002-10-11 2005-08-03 Ligand Pharmaceuticals, Inc. 5-(1 ,1 -CYCLOALKYL/ALKENYL)METHYLIDENE 1,2-DIHYDRO- 5H /-CHROMENO[3,4-f ] QUINOLINES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS
WO2004035883A2 (en) * 2002-10-17 2004-04-29 Nexen Nano Tech Co., Ltd Fibrous nano-carbon and preparation method thereof
EP1620075B1 (en) * 2003-05-07 2020-06-24 Samyang Biopharmaceuticals Corporation Highly plastic granules for making fast melting tablets
AR047398A1 (es) * 2003-11-24 2006-01-18 Wyeth Corp Acoplamiento cruzado carbono- carbono catalizado por metales de transicion sobre soportes solidos
EP1691746B1 (en) * 2003-12-08 2015-05-27 Gel-Del Technologies, Inc. Mucoadhesive drug delivery devices and methods of making and using thereof
CN1672685A (zh) * 2004-03-26 2005-09-28 董可娟 一种新的避孕药物
US7399870B2 (en) * 2004-03-30 2008-07-15 Wyeth Synthesis of pyrrole-2-carbonitriles
EP1732922B1 (en) * 2004-04-08 2008-10-01 Wyeth Methods for minimizing thioamide impurities
CA2561014C (en) * 2004-04-08 2013-09-10 Wyeth Thioamide derivatives as progesterone receptor modulators
CN1946665B (zh) * 2004-04-08 2011-06-15 惠氏公司 3-环戊氧基-4-甲氧基苯甲醛的制备方法
JP5039541B2 (ja) * 2004-04-27 2012-10-03 ワイス・エルエルシー プロゲステロン受容体調節剤の精製
SV2005002092A (es) * 2004-04-27 2005-12-13 Wyeth Corp " proceso de acoplamiento para la generacion de derivados reactivos de pirrol-2-carbonitrilo n-sustituidos con contenido de boro para producir biarilos " ref. am - 101481salvo.
BRPI0510278A (pt) * 2004-04-27 2007-10-30 Wyeth Corp método para produzir compostos, produto, e, composto
JP5288796B2 (ja) 2004-07-07 2013-09-11 ワイス・エルエルシー 周期的プロゲスチンレジメン及びキット
GT200500183A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
SI1778710T1 (sl) * 2004-08-13 2012-05-31 Wyeth Llc Derivati tanaprogeta metaboliti in njihove uporabe
BRPI0514528A (pt) 2004-08-20 2008-06-10 Wyeth Corp estrutura de receptores de progesterona
JP4197684B2 (ja) * 2005-03-23 2008-12-17 株式会社東芝 携帯無線機
PL1877059T3 (pl) 2005-04-28 2010-07-30 Wyeth Llc Mikroniozowany tanaproget i zawierające go kompozycje
CN101166736B (zh) * 2005-04-28 2013-02-06 惠氏公司 他那普戈特的多晶型ⅱ
PT1896034E (pt) * 2005-04-28 2010-05-06 Wyeth Llc Composições de tanaproget micronizado e métodos para a sua preparação
ES2431324T3 (es) 2005-04-28 2013-11-26 Wyeth Llc Forma purificada de tanaproget
CN101166521A (zh) 2005-04-28 2008-04-23 惠氏公司 通过湿制粒法制备包含微粒化他那普戈特的组合物
JP2008540337A (ja) * 2005-04-29 2008-11-20 ワイス ３，３−二置換オキシインドールおよびチオ−オキシインドールを調製する方法
KR100733419B1 (ko) * 2005-04-30 2007-06-29 주식회사 하이닉스반도체 내부전원 생성장치
US20060293295A1 (en) * 2005-05-13 2006-12-28 Kai Strothmann Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl- (6S)-tetrahydrofolate
UY29527A1 (es) * 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
WO2006128057A2 (en) * 2005-05-26 2006-11-30 Duramed Pharmaceuticals, Inc. Oral dosage forms comprising progesterone and methods of making and using the same
CA2610767C (en) * 2005-06-09 2014-09-23 Wyeth Tanaproget compositions containing ethinyl estradiol
CA2619503A1 (en) * 2005-06-28 2007-01-04 Robert F. Casper Aromatase inhibitors for emergency contraception
PE20070404A1 (es) * 2005-07-29 2007-05-10 Wyeth Corp Compuestos derivados de cianopirrol-sulfonamida como moduladores del receptor de progesterona
PE20070182A1 (es) * 2005-07-29 2007-03-06 Wyeth Corp Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona
PE20070341A1 (es) * 2005-07-29 2007-04-13 Wyeth Corp Derivados de pirrol como moduladores del receptor de progesterona
TW200740782A (en) * 2005-09-01 2007-11-01 Tanabe Seiyaku Co Thiomorpholine compound and process for preparing the same
US20070066628A1 (en) * 2005-09-19 2007-03-22 Wyeth 5-Aryl-indan-1-ol and analogs useful as progesterone receptor modulators
US7319152B2 (en) * 2005-09-19 2008-01-15 Wyeth 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
US20070093548A1 (en) * 2005-10-25 2007-04-26 Wyeth Use of progesterone receptor modulators
US20070213526A1 (en) * 2006-03-07 2007-09-13 Wyeth Purification of progesterone receptor modulators
TW200810231A (en) * 2006-08-11 2008-02-16 Hon Hai Prec Ind Co Ltd Antenna device
AU2007338843B2 (en) * 2006-12-20 2013-05-09 Teva Women's Health, Inc. Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof

Also Published As

Publication number Publication date
EP2234491A1 (en) 2010-10-06
US20090170823A1 (en) 2009-07-02
AU2008341138A1 (en) 2009-07-02
WO2009082478A1 (en) 2009-07-02
IL206465A0 (en) 2010-12-30
JP2011507853A (ja) 2011-03-10
CA2710293A1 (en) 2009-07-02
EA201070715A1 (ru) 2011-02-28
JP2014193918A (ja) 2014-10-09
EP2234491A4 (en) 2010-12-22

Similar Documents

Publication Publication Date Title
BRPI1011815A2 (pt) "composição farmacêutica para a contracepção de emergência"
BRPI1014865A2 (pt) "composição e formulação farmacêutica comreendendo derivados de nitrocatecol, e, método para fabricar uma composição ou formulação farmacêutica"
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0818533A2 (pt) composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0807807A2 (pt) " composição farmacêutica de liberação modificada e um processo para fabricar a mesma ".
BRPI0810928A2 (pt) "composição farmacêutica"
BRPI0813201A2 (pt) "composição curável, compósito e método para formar um compósito"
BRPI0720232A2 (pt) Produto de cloridrato de oximorfona, formulação farmacêutica, método para purificar cloridrato de oximorfona, e, produto de cloridrato de oximorfona
BRPI0816513A2 (pt) Composição farmacêutica e método para preparar a suspensão sólida
BRPI0817917A2 (pt) Implemento para cuidado oral, e, método para formar um implemento para cuidado oral
BRPI0808293A2 (pt) "composições para administração nasal"
BRPI0816553A2 (pt) "composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto"
BRPI0914371A2 (pt) "composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo, e produto de combinação"
BRPI0916102A2 (pt) "método para a prevenção da hérnia paraestomal, método para preparar uma hérnia paraestomal e dispositivo para preparar ou reduzir a incidência da hérnia paraestomal"
BRPI0819534A2 (pt) Composição farmacêutica, método para tratar hiv ou aids e método para preparar uma composição farmacêutica, forma de dosagem e composição"
BR112012003462A2 (pt) "composto, composição farmacêutica, e, método para tratar um paciente tendo uma condição mediada pela proteína quinase."
EP2199402A4 (en) CYCLOASTRAGENOL MONOGLYCOSIDE, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0903914A2 (pt) Uso de um composto, método para analisar a eficácia de uma composição de liberação prolongada, e, composição farmacêutica.
BRPI0807001A2 (pt) Formulação farmacêutica, e, método para preparação de uma formulação farmacêutica.
PT2231598E (pt) Novos derivados diazéniodiolato, processo para a sua preparação e as composições farmacêuticas que os contenham
BRPI0819571A2 (pt) "método para contracepção de emergência, pacote farmacêutico para contracepção de emergência e composição farmacêutica"
BRPI0906045A2 (pt) "composição farmacêutica para administração nasal"
BRPI0813658A2 (pt) composto, medicamento, composição farmacêutica, preparação farmacêutica combinada, usos de um composto e de uma preparação combinada, e, processo para a preparação de composto.
BRPI1010563A2 (pt) "formulação oleosa de mitotano, método para o preparo da mesma e composição farmacêutica"

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.